Please assess the completion status of the following clinical trial:

Trial Title: Repeated Mesenchymal Stem Cell Injections in ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ages 18 to 70 years old, at the Screening Visit.~2. Sporadic or familial ALS diagnosed patients fulfilling the El Escorial clinical criteria for definite.~3. Capable of providing informed consent and willing and able to follow study procedures, including willingness to undergo multiple/repeated lumbar punctures.~4. ALSFRS-R ≥15 at the Screening Visit.~Exclusion Criteria:~1. Patients with severe cognitive decline or inability to understand and sign the informed consent.~2. Participation in another clinical trial within 1 year prior to start of the study~3. Patients with active infections.~4. Positive test for Hepatitis B, Hepatitis C, and/or HIV per laboratory evaluations at the screening visit.~5. Any history of solid malignancy including any malignancy affecting the central nervous system within 5 years of the Screening Visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Repeated MSCs treatment in ALS patients (Type: EXPERIMENTAL): Four intrathecal (IT) administrations of autologous MSC cells administered every 3 months in ALS patients. the IT treatment will be administered through a regular lumbar puncture at a dose of 1x10\^6 MSCs per kg body weight in 3 ml saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).